Combinatorial anti-tumor efficacy of ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) in advanced stage melanoma and renal cell carcinoma (RCC) highlights the importance of targeting multiple immune pathways to unleash a more robust anti-tumor immune response (2, 3). The gene discussed is CTLA4; the disease is renal cell carcinoma.